Patents Assigned to Geron Corporation
  • Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
    Patent number: 9155753
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 13, 2015
    Assignee: Geron Corporation
    Inventors: Robert J. Tressler, Ning F. Go
  • RNA amidates and thioamidates for RNAi
    Patent number: 9133233
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: September 15, 2015
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase
    Publication number: 20150250863
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 10, 2015
    Applicants: The Regents of the University of Colorado, Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Oligonucleotide conjugates
    Patent number: 9072790
    Abstract: Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: July 7, 2015
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Richard L. Tolman, Gregg B. Morin
  • SYNTHESIS OF PROTECTED 3'-AMINO NUCLEOSIDE MONOMERS
    Publication number: 20150038692
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Application
    Filed: May 13, 2014
    Publication date: February 5, 2015
    Applicant: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • 2?-arabino-fluorooligonucleotide N3??P5? phosphoramidates: their synthesis and use
    Patent number: 8906615
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(?O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-aribino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: December 9, 2014
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz
  • Compounds Having Anti-Adhesive Effects on Cancer Cells
    Publication number: 20140329890
    Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3??P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Applicants: GERON CORPORATION, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sergei M. Gryaznov, Jerry W. Shay, Woodring Wright
  • Method for identification of sensitivity of a patient to telomerase inhibition therapy
    Patent number: 8877723
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: November 4, 2014
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Telomere Length Measurement in Formalin-Fixed, Paraffin Embedded (FFPE) Samples by Quantitative PCR
    Publication number: 20140248622
    Abstract: Methods of reliably quantifying telomere length in cells or tissues that have been formalin fixed and paraffin embedded (FFPE) samples by quantitative polymerase chain reaction protocol and kits for use with such various methods are provided. The methods of the present invention may be used to predetermine an individual's response to treatment with a telomerase inhibitor, a telomere damaging agent or a telomerase activator.
    Type: Application
    Filed: March 26, 2012
    Publication date: September 4, 2014
    Applicant: Geron Corporation
    Inventors: Hui Wang, Ning F. Go, Zhu Zhen Pirot
  • Nucleic acids encoding inactive variants of human telomerase
    Patent number: 8796438
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically inactive variants comprising deletions or other mutations are provided.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: August 5, 2014
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventor: Gregg B. Morin
  • Compounds having anti-adhesive effects on cancer cells
    Patent number: 8785409
    Abstract: Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3??P5? thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: July 22, 2014
    Assignees: Geron Corporation, Board of Regents of the University of Texas System
    Inventors: Sergei M. Gryaznov, Jerry W. Shay, Woodring Wright
  • Synthesis of protected 3?-amino nucleoside monomers
    Patent number: 8748593
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: June 10, 2014
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
    Publication number: 20140134729
    Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 15, 2014
    Applicant: GERON CORPORATION
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED CARDIOMYOCYTES
    Publication number: 20140134725
    Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.
    Type: Application
    Filed: September 17, 2013
    Publication date: May 15, 2014
    Applicant: Geron Corporation
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • Method for eliciting an immune response to human telomerase reverse transcriptase
    Patent number: 8709995
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 29, 2014
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Differentiation and Enrichment of Islet-Like Cells from Human Pluripotent Stem Cells
    Publication number: 20130337561
    Abstract: Methods for differentiating human pluripotent stem cells into islet-like cells are provided. In certain embodiments, the methods utilize sequential culturing of the human pluripotent stem cells with certain factors to produce islet-like cells. In certain embodiments, the population of cells produced by the methods is further enriched for islet-like cells.
    Type: Application
    Filed: March 8, 2013
    Publication date: December 19, 2013
    Applicant: Geron Corporation
    Inventors: Anish Sen Majumdar, JianJie Jiang, Melinda Au
  • Synthetic surfaces for culturing stem cell derived cardiomyocytes
    Patent number: 8563312
    Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: October 22, 2013
    Assignee: Geron Corporation
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • Compound screening using chondrocytes derived from primate pluripotent stem cells
    Patent number: 8546101
    Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: October 1, 2013
    Assignee: Geron Corporation
    Inventor: R. Scott Thies
  • Protocols for making hepatocytes from embryonic stem cells
    Patent number: 8546139
    Abstract: This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: October 1, 2013
    Assignee: Geron Corporation
    Inventors: Ramkumar Mandalam, Saadia Faouzi, Isabelle Nadeau, Kristina Pfendler-Bonham, Namitha Rao, Melissa K. Carpenter, Lakshmi Rambhatla, Choy-Pik Chiu
  • Oligonucleotide Conjugates
    Publication number: 20130253042
    Abstract: Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity.
    Type: Application
    Filed: May 10, 2013
    Publication date: September 26, 2013
    Applicant: Geron Corporation
    Inventors: Sergei M. Gryaznov, Krisztina Pongracz, Richard L. Tolman, Gregg B. Morin